Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), blocks both IL-4 and IL-13 signaling and is approved for several type 2 inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. This evidence concerns the gene IL13 and atopic eczema.